[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"upper-abdominal-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:upper-abdominal-pain":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100574160","a-prospective-multicentre-real-world-assessment-of-the-efficacy-of-danning-tablets-in-alleviating-digestive-symptoms-100574160",false,"NCT06755671","A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms","Inclusion Criteria:\n\n* Patients between 18 and 75 years old\n* Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation\n* Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia\n* Patients agree to sign the informed consent form\n\nExclusion Criteria:\n\n* Past history or comorbidity of malignant tumor\n* Comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases\n* Past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden)\n* Comorbidity of any unstable chronic or acute disease,which may impact the evaluation of treatment efficacy as determined by the research physician\n* Pregnancy or breastfeeding\n* Participation in other clinical trials within the past 3 months\n* Other circumstances determined as ineligible by the research physician","ALL","18 Years","75 Years",{"count":19,"type":20},4500,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation.\n\nThe main questions it aims to answer are:\n\nHow effective are Danning Tablets for patients with indigestion symptoms? What are the impact factors (e.g. severity of conditions, demographic features, dose and length of treatment etc.) of the efficacy of Danning Tablets for indigestion patients?\n\nParticipants already taking Danning Tablets as part of their regular medical care for indigestion will take questionnaires by the end of two weeks and four weeks respectively from the start of their treatment.",[24,25,26,27,28,29,30,31],"Indigestion","Dyspepsia","Bloating","Loss of Appetite","Reflux Acid","Constipation","Upper Abdominal Pain","Functional Dyspepsia",[33,34,35,36,37],"Danning Tablets","dyspepsia","indigestion","observational study","real world study","RECRUITING","2025-05-13",{"date":41,"type":42},"2025-05-14","ACTUAL",{"date":44,"type":42},"2025-04-30",{"date":46,"type":20},"2027-06-30",{"name":48,"class":49},"Shanghai Hutchison Pharmaceuticals Limited","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":73,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100516284","relief-pathway-in-patients-with-upper-abdominal-pain-100516284","NCT06002516","RELIEF-pathway in Patients With Upper Abdominal Pain","The RELIEF-pathway in Patients With Upper Abdominal Pain; an Open-label Multicenter Randomized Controlled Trial","RELIEF","Inclusion Criteria:\n\n* Patients between 18 and 70 years old.\n* First referral due to upper abdominal pain (UAP) and symptoms due to Functional dyspepsia (ICPC code 87.02), Irritable Bowel syndrome (ICPC 93.0) or uncomplicated symptomatic cholecystolithiasis (ICPC 98.03).\n* Proficient in reading and understanding of the Dutch language.\n* Referred to the outpatient clinic of gastroenterology or surgery.\n* Providing informed consent.\n\nExclusion Criteria:\n\n* If the following alarm symptoms are reported in the referral letter by the GP: weight loss, persistent vomiting, dysphagia, jaundice, hematemesis, melena, haematochezia, or anaemia.\n* Any other direct or indirect signs of cancer or upper GI tract bleeding.\n* Patients with a first or second-degree relative with a history of upper GI tract malignant neoplasm.\n* Patients with a history of complicated cholecystolithiasis.\n* A history of or current malignancy (except SCC or BCC of the skin).\n* Pregnancy;\n* Expected short life span of less than 12 months.\n* Known cirrhosis of the liver\n* Current schizophrenia, memory deficiency, or any other disorder that predispose them to unreliable questionnaire responses;\n* Mentally incompetent;","70 Years",{"count":61,"type":20},471,"INTERVENTIONAL",[64],"NA","Upper abdominal pain (UAP) is a common symptom and frequently the reason to visit the hospital. The prevalence of epigastric pain in the Dutch population is estimated to be as high as 37%. Moreover, Dutch hospitals yearly record \\>100.000 diagnoses related to UAP. In most patients, UAP can be attributed to symptomatic (functional) dyspepsia (FD), Irritable Bowel Syndrome (IBS) or uncomplicated gallstone disease (cholecystolithiasis), with a prevalence in the general population of 20-30%, 20%, and 6-9%, respectively. However, these conditions may have overlapping symptom patterns and generally affect similar populations. which contributes to ineffective (diagnostic) interventions. Patients are generally not aware of the similarity of symptoms and the poor outcome of some treatments.\n\nEducation positively influences patients' self-management and health judgment. In a recent open-label, multicentre trial the effectiveness of web-based patients' education is applied to reduce overuse of upper gastrointestinal endoscopies in patients with dyspepsia. This study illustrated that an web-based education tool safely reduced 40% in upper gastrointestinal endoscopies. Lifestyle interventions (such as change of diet and\u002For physical activity) are widely incorporated in treatment programs for cardio-vascular diseases including diabetes mellitus and obesity. An web-based education tool on upper abdominal pain and other complaints combined with a lifestyle interventions for patients may be an effective treatment option for this large group of patients.\n\nThis study investigates the potential of an individualized web-based education tool as intervention for patients with functional dyspepsia, irritable bowel syndrome and uncomplicated symptomatic cholecystolithiasis with the possibility to visit the Prevention and Lifestyle clinic (RELIEF pathway). The RELIEF pathway aims to reduce unnecessary health care utilization and, secondly, to maintain and improve quality of life by educating patients on lifestyle improvement.",[67,68,25,69,70,71,30,72],"Abdominal Pain","Gallstone; Colic","Irritable Bowel Syndrome","Health Care Utilization","Patient Reported Outcomes","Decision Aid",[74,75],"Abdominal pain","Health care utilization","NOT_YET_RECRUITING","2023-08-15",{"date":79,"type":42},"2023-08-21",{"date":81,"type":20},"2024-05-01",{"date":83,"type":20},"2027-05-01",{"name":85,"class":86},"Radboud University Medical Center","OTHER"]